adverse events of interest requires consideration of how these may present in neonatal/paediatric patients.

Conclusions In order to support the protocol development with regards to neonatal/paediatric drug safety a dual competence in both paediatrics and drug safety is required. This review provides an overview of the practical aspects related to neonatal/paediatric drug safety during protocol development.

Disclosure(s) Nothing to disclose

### P12 PUBLIC ANTIBIOTIC AWARENESS CAMPAIGN ORGANISED BY GOVERNMENT SIGNIFICANTLY REDUCED INAPPROPRIATE ANTIBiotic USE IN PAEDIATRIC PRIMARY CARE SETTINGS

Serbia, like most other countries in southern Europe, has struggled with high rate of antibiotic consumption. Previous results showed that most of antibiotics were prescribed inappropriately, mainly for influence - like illness\(^1\). The first short term media antibiotic awareness campaign (AAC) was held in 2011 and 2014, respectively. Shortly after, Ministry of Health, Republic of Serbia in November 2015 has started with public AAC simultaneously across all regions of Republic of Serbia.

Apart from media, the campaign included education, producing national guidelines, as well as regulations. The education goals for public (preschool and school children, parents, pregnant women, students) and healthcare professionals (paediatricians, nurses, pharmacists, etc.) was based on results of analysis of antibiotic consumption in children from 2007 to 2014. which methodology was published previously.\(^1\) Media campaign included public relations activities, press conferences, billboards, printed materials, etc.

In 2017, prescribing rates of antibiotics per 1000 children in primary care settings were decreased by 18\% comparing to 2011, after first and by 12\% comparing to 2014, when second short term media campaign was performed. After the third, government organised public AAC, prescribing rates of antibiotics per 1000 children in primary care settings were decreased by 6\% for only one year (2017 vs. 2016) in all age groups from 2 months up to 17 years. Significant decrease of prescribed rate of antibiotics per 1000 children during 2017 was recorded for indication with policy of delayed or no antibiotic prescription recommended by guidelines. Seasonal oscillations showed that highest prescribing rate during the winter months (I and the IV quarter) of 2017 is in line with the lowest prescribing rate during the summer months (II and the III quarter) from 2007 up to 2013.

We can conclude that continuous antibiotic awareness campaign supported by state government is the best way to achieve successful results.

### REFERENCES


Disclosure(s) Nothing to disclose

### P13 SERIOUS ADVERSE REACTIONS AND OFF LABEL AND UNLICENSED DRUG USE IN CHILDREN – DECADE OF PHARMACOVIGILANCE STUDY IN SERBIA

Background Off label (OL) and unlicensed (UL) drug use in children is a widespread global problem. Previous study showed that only 66\% of all available drugs for children is with licence in Serbia.\(^1\) Data on safety of medicines in children remain lacking, so the key intervention for the effective use of medicine is safety monitoring. Therefore, the aim of this study is to evaluate safety implication of OL and UL drug use in children up to 12 years old.

Method We conducted a retrospective study based on reports of suspected adverse reactions (ADRs) collected from 2008 to 2018, by Medicines and Medical Devices Agency of Serbia, using the Medical Dictionary for Regulatory Activities and organized by System Organ Class. Sources of information about medicines including vaccines (license, drug formulation, etc.) are the Summary of Product Characteristics and Serbia’s official drug registry.

Results Within 10 years, we observed 1595 ADRs. Vaccines, antineoplastic and antimicrobial drugs were the most frequently pharmacothe applies in subgroups involved. Out of total number of observed ADRs, 433 (28\%) were serious; 189 of them led to hospitalization, 31 to life threatening conditions and 7 were fatal. More than a half (63\%) of serious ADRs were detected in children for the age group of 28 days - 23 months, followed by the age group of 2 to 11 years (34\%) and finally by age group of 0 to 27 days (3\%). Serious ADRs were detected in boys (55\%) as well as in girls (45\%). Out of total number of registered only 3\% (46) of ADRs were associated with off-label use; 18 of them were serious, 7 led to life threatening conditions and 3 were fatal.

Conclusion This research provided new insight on the factors such as OL and UL use, that might increase the risk of serious ADRs in children.

### REFERENCES


Disclosure(s) Nothing to disclose

### P14 PHARMACOVIGILANCE IN PEDIATRIC PATIENTS: THE CHALLENGE OF IDENTIFYING NEW SIGNAL

Introduction The importance of reporting adverse drug reactions (ADRs) is well known. However, the reporting rate is very low, and therefore, identifying new signal is challenging.

Objective To create an interventional program in order to improve reporting rate and trying to identify new signal.
Material and methods The interventional program was implemented at the Pediatric Division of Assaf Harofeh Medical Center and included presentations to the healthcare professionals, posters, creating new ADRs reporting methods and alerts.

Results Reporting rate of ADRs during the year before implementation of the program was negligible. During the study period (three months), the reporting rate increased dramatically. A new signal was reported; two neonates with apnea related to IVIG administration in the neonatology department. The distribution of reports was: 50% from the pediatric department, 26% - pediatric neurology department, 21% and 6%, from the pediatric and neonatal intensive care units, respectively. Steroids and antibiotics were responsible for various ADRs, but not for a new signal.

Conclusion There is one case report in the literature on apnea related to IVIG administration. Adverse reactions in children are a major problem and sometimes can lead to morbidity mortality. Identifying new signal in pediatric patients is not common, and very challenging.

Disclosure(s) Nothing to disclose

Conclusion Large studies, preferably prospective, on lacosamide serum monitoring including information on correlation with efficacy and safety are warranted.

Disclosure(s) Nothing to disclose